Gilgamesh nets $60M Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T Wed Th F 25 March, 2026

Every year, John Carroll sizes up the top 15 global pharma pipelines — then brings the findings live with the R&D chiefs shaping them. What's in, what's out, and what's next for 2026? Register now.

presented by Fu­ji­film ex­pands glob­al life sci­ences foot­print through large-scale bio­man­u­fac­tur­ing in­vest­ments

SPOTLIGHT Who’s leading LGBTQ+ inclusion in biopharma? Nominate them for Endpoints’ annual report

news Merck to buy Terns for $6.7B, taking a leukemia drug that could challenge Scemblix Maze meets own expectations in Phase 2 kidney disease trial in the same arena as Vertex Gilgamesh's psychedelics pipeline gets $60M backing after AbbVie deal

Head of Regulatory Strategy TCG stealth clinic-ready newco Boston, MA, USA Senior Director, Licensing Officer Bayer Cambridge, MA, USA Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

US biopharma still leads the world in high-risk drug development, but the road from innovation to access has never been harder to predict. Hear from top executives and investors on how they’re navigating what’s next. Join us.

ENDPOINTS PHARMA FDA warns ImmunityBio over misleading podcast with Patrick Soon-Shiong Biotech investors will meet with congressional panel, pushing US competitiveness changes Q&A: Embryo editing entrepreneur Cathy Tie closes one startup and begins another in biology’s most taboo frontier

in case you missed it 1. Gilead bets $1.68B upfront on Ouro Medicines’ autoimmune program, with Galapagos expected to pitch in 2. Ocugen heads to Phase 3 with gene therapy to prevent vision loss from macular degeneration 3. News Briefing Karyopharm’s mixed myelofibrosis data; Rezolute to seek FDA approval despite trial failure 4. UK biotech co-founded by Nobel laureate secures $86M for antibody program 5. Shionogi will pay $100M to buy out Apnimed's part of their sleep disorder partnership 6. Merck partners with Flagship's 'somatic genomics' startup to search for clues to IBD 7. Key Adviser Quits Federal Vaccine Panel 8. Roche Restricts Consulting Work With Big Four Firms to Cut Costs